Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: The Bosentan Patient Registry

    Access Status
    Fulltext not available
    Authors
    Owen, A.
    Spinks, J.
    Meehan, A.
    Robb, T.
    Hardy, M.
    Kwasha, D.
    Wlodarczyk, J.
    Reid, Christopher
    Date
    2008
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Owen, A. and Spinks, J. and Meehan, A. and Robb, T. and Hardy, M. and Kwasha, D. and Wlodarczyk, J. et al. 2008. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: The Bosentan Patient Registry. Journal of Medical Economics. 11 (2): pp. 235-243.
    Source Title
    Journal of Medical Economics
    DOI
    10.3111/13696990802034525
    ISSN
    1369-6998
    School
    Department of Health Policy and Management
    URI
    http://hdl.handle.net/20.500.11937/8622
    Collection
    • Curtin Research Publications
    Abstract

    Backgound: Pharmaceutical subsidy schemes are under increasing pressure to evaluate the cost effectiveness of new highly specialised and orphan drugs for universal subsidy. In the absence of longer-term outcome data, drug sponsors often present modelled data, which can carry a significant level of uncertainty over longer-term projections. Risk-sharing schemes between drug sponsor and government may provide an acceptable method of balancing the uncertainty of longer-term cost effectiveness with the public demand for equitable and timely access to new drugs. Methods: The Bosentan Patient Registry (BPR) is an example of a unique risk-sharing model utilised in Australia aiming to provide clinical evidence to support the modelled predictions, with the registry survival outcomes linked to future price. Concomitant medication, health and vital status data was collected from clinicians, government health departments and death registries. Results: The BPR has identified a number of issues surrounding registry governance, ethics and patient privacy, and the collection of timely and accurate data, which need to be addressed for the development of a generic registry model for systematic evaluation. Conclusion: The success of a generic drug registry model based on the BPR will be enhanced by addressing a number of operational issues identified during the implementation of this project. © 2008 Informa UK Ltd.

    Related items

    Showing items related by title, author, creator and subject.

    • Design of a framework for the deployment of collaborative independent rare disease-centric registries: Gaucher disease registry model
      Bellgard, M.; Napier, K.; Bittles, A.; Szer, J.; Fletcher, S.; Zeps, Nikolajs; Hunter, A.; Goldblatt, J. (2016)
      Orphan drug clinical trials often are adversely affected by a lack of high quality treatment efficacy data that can be reliably compared across large patient cohorts derived from multiple governmental and country ...
    • Pharmacodynamic studies of antimalarial drugs in a murine malaria model
      Moore, Brioni R. (2011)
      Murine malaria models have proved to be a valuable preclinical tool, particularly in the development of new concepts in the research of human malaria. Plasmodium berghei (P. berghei), is the most extensively studied and ...
    • The Asia-Pacific Evaluation of Cardiovascular Therapies (ASPECT) Collaboration - Improving the quality of cardiovascular care in the Asia Pacific Region
      Reid, Christopher; Yan, B.; Wan Ahmad, W.; Bang, L.; Hian, S.; Chua, T.; Chan, M.; Beltrame, J.; Duffy, S.; Brennan, A.; Ajani, A. (2014)
      Background Clinicians and other stakeholders recognize the need for clinical registries to monitor data in order to improve the outcome and quality of care in the delivery of medical interventions. The establishment of a ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.